ArticleFrontiers in psychiatry2019
A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 6 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Examining the Transition from Single Words to Phrase Speech in Children with ASD: A Systematic Review.Clinical child and family psychology review · 2024Pooled it
- Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).The Cochrane database of systematic reviews · 2023Pooled it
- Psychopharmacological treatment of disruptive behavior in youths: systematic review and network meta-analysis.Scientific reports · 2023Pooled it
- Benefits and harms of interventions to improve anxiety, depression, and other mental health outcomes for autistic people: A systematic review and network meta-analysis of randomised controlled trials.Autism : the international journal of research and practice · 2023Pooled it
- Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.Molecular autism · 2020Pooled it
- Therapeutic effects of antidepressants for global improvement and subdomain symptoms of autism spectrum disorder: a systematic review and meta-analysis.Journal of psychiatry & neuroscience : JPNPooled it
- Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial.Nature medicine · 2022Trial
- Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges.World journal of clinical pediatrics · 2026Article
- Selective Serotonin Reuptake Inhibitors for Children with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.Clinical medicine insights. Pediatrics · 2026Review
- Genetic variability and response to sertraline in pediatric populations: a review on pharmacogenetics, pharmacokinetics, and the risk of adverse events.Frontiers in child and adolescent psychiatry · 2026Review
- Utilization of psychotropic medications in individuals with autism spectrum disorder.BMC psychiatry · 2025Article
- Pharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy.Biomedicines · 2025Review
- Autism Spectrum Disorder and Epilepsy: Pathogenetic Mechanisms and Therapeutic Implications.Journal of clinical medicine · 2025Review
- Prevalence of fragile X syndrome in South Asia, and importance of diagnosis.Medical review (2021) · 2025Review
- Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials: Antidepressants for Restricted and Repetitive Behaviors in Autism Spectrum Disorder.Neuropsychiatric disease and treatment · 2024Review
- Neurodevelopment and early pharmacological interventions in Fragile X Syndrome.Frontiers in neuroscience · 2023Review
- A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.Experimental brain research · 2022Review
- An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis.BJPsych open · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Laura A PotterMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Health, Sacramento, CA, United States.
Danielle A ScholzeDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Hazel Maridith B BiagMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Health, Sacramento, CA, United States.
Andrea SchneiderMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Health, Sacramento, CA, United States.
Yanjun ChenInstitute for Clinical and Translational Science, University of California, Irvine, Irvine, CA, United States.
Danh V NguyenDepartment of Medicine, University of California, Irvine School of Medicine, Orange, CA, United States.
Akash RajaratnamCase Western Reserve University School of Medicine, Cleveland, OH, United States.
Susan M RiveraMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Health, Sacramento, CA, United States.
Patrick S DwyerDepartment of Psychology, University of California, Davis, Davis, CA, United States.
Flora TassoneMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Health, Sacramento, CA, United States.
Reem R Al OlabyCollege of Health Sciences, California Northstate University, Rancho Cordova, CA, United States.
Nimrah S ChoudharyDepartment of Biochemistry and Molecular Medicine, UC Davis Health, Sacramento, CA, United States.
Maria J Salcedo-ArellanoMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Health, Sacramento, CA, United States.
Randi J HagermanMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Health, Sacramento, CA, United States.
UC Davis Health System · USUniversity of California, Davis · USUniversity of California, Irvine · USCalifornia Northstate University · USCase Western Reserve University · USUniversity of Wisconsin–Madison · US
Funding
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1MInterdisciplinary Training for Autism Researchers(RMI)T32MH073124 · NIMH · UNIVERSITY OF CALIFORNIA DAVIS · PI Stephen Charles Noctor, Christine Wu Nordahl · 2004 to 2026
$6.8MNCATS NIH HHS UL1 TR001414
Abstract
PubMed holds no abstract for this paper.
Indexed as
autism spectrum disordercontrolled trialnonsyndromic autism spectrum disordersertralinetargeted treatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.